LifeMD (NASDAQ:LFMD) Cut to Strong Sell at Zacks Research

Zacks Research cut shares of LifeMD (NASDAQ:LFMD) from a hold rating to a strong sell rating in a research report report published on Thursday morning,Zacks.com reports.

Other analysts also recently issued research reports about the company. BTIG Research cut their price target on LifeMD from $18.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Mizuho cut their target price on LifeMD from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday. Lake Street Capital reduced their price target on LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeMD in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, LifeMD presently has a consensus rating of “Hold” and an average price target of $9.43.

LifeMD Stock Up 3.8%

NASDAQ LFMD opened at $3.85 on Thursday. The firm’s 50-day simple moving average is $5.88 and its two-hundred day simple moving average is $8.60. The company has a market cap of $185.34 million, a PE ratio of -22.65 and a beta of 1.57. LifeMD has a 52 week low of $3.43 and a 52 week high of $15.84.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Monday, November 17th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The company had revenue of $60.17 million for the quarter, compared to analyst estimates of $62.07 million. During the same quarter in the prior year, the firm earned $0.09 earnings per share. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts anticipate that LifeMD will post -0.56 EPS for the current year.

Insider Activity at LifeMD

In other news, insider Nicholas P. Alvarez sold 75,000 shares of LifeMD stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $5.92, for a total value of $444,000.00. Following the completion of the sale, the insider directly owned 605,000 shares in the company, valued at $3,581,600. The trade was a 11.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 18.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LifeMD

A number of large investors have recently added to or reduced their stakes in LFMD. Y Intercept Hong Kong Ltd purchased a new stake in LifeMD during the second quarter valued at approximately $818,000. Acadian Asset Management LLC bought a new position in shares of LifeMD in the second quarter worth about $3,828,000. Wealthspire Advisors LLC bought a new position in LifeMD in the 2nd quarter worth approximately $840,000. Nuveen LLC purchased a new stake in LifeMD in the 1st quarter worth $1,545,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of LifeMD in the second quarter worth about $193,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.